{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T04:41:09Z","timestamp":1771562469768,"version":"3.50.1"},"publisher-location":"Cham","reference-count":33,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783030663056","type":"print"},{"value":"9783030663063","type":"electronic"}],"license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019]]},"DOI":"10.1007\/164_2019_308","type":"book-chapter","created":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T14:02:54Z","timestamp":1592575374000},"page":"171-184","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Use of Botulinum Toxin in the Genitourinary System"],"prefix":"10.1007","author":[{"given":"Michael B.","family":"Chancellor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher P.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,20]]},"reference":[{"key":"308_CR1","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1097\/01.AOG.0000237100.29870.cc","volume":"108","author":"JA Abbott","year":"2006","unstructured":"Abbott JA, Jarvis SK, Lyons SD et al (2006) Botulinum toxin type A for chronic pain and pelvic floor spasm in women. Obstet Gynecol 108:915\u2013923","journal-title":"Obstet Gynecol"},{"issue":"6","key":"308_CR2","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1016\/j.juro.2010.08.028","volume":"184","author":"TA Abdel-Meguid","year":"2010","unstructured":"Abdel-Meguid TA (2010) Botulinum toxin-A injections into neurogenic overactive bladder--to include or exclude the trigone? A prospective, randomized, controlled trial. J Urol 184(6):2423\u20132428","journal-title":"J Urol"},{"key":"308_CR3","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/nau.10052","volume":"21","author":"P Abrams","year":"2002","unstructured":"Abrams P, Cardozo L, Fall M et al (2002) The standardization of terminology of lower urinary tract function: report from the standardisation sub-committee of the international continence society. Neurourol Urodyn 21:167\u2013178","journal-title":"Neurourol Urodyn"},{"key":"308_CR4","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1097\/SPV.0b013e3182989fd8","volume":"19","author":"A Adelowo","year":"2013","unstructured":"Adelowo A, Hacker MR, Shapiro A et al (2013) Botulinum toxin type A (BOTOX) for refractory myofascial pelvic pain. Female Pelvic Med Reconstr Surg 19:288\u2013292","journal-title":"Female Pelvic Med Reconstr Surg"},{"key":"308_CR5","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1001\/jama.2016.14617","volume":"316","author":"CL Amundsen","year":"2016","unstructured":"Amundsen CL, Richter HE, Menefee SA et al (2016) OnabotulinumtoxinA vs sacral neuromodulation on refractory urgency urinary incontinence in women: a randomized clinical trial. JAMA 316:1366\u20131374","journal-title":"JAMA"},{"key":"308_CR6","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.eururo.2005.12.010","volume":"49","author":"A Apostolidis","year":"2006","unstructured":"Apostolidis A, Dasgupta P, Fowler CJ (2006) Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol 49:644\u2013650","journal-title":"Eur Urol"},{"key":"308_CR7","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/mus.10213","volume":"26","author":"CR Billante","year":"2002","unstructured":"Billante CR, Zealear DL, Billante M et al (2002) Comparison of neuromuscular blockade and recovery with botulinum toxins A and F. Muscle Nerve 26:395\u2013403","journal-title":"Muscle Nerve"},{"key":"308_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-03580-7","volume-title":"Botulinum toxin in urology","author":"MB Chancellor","year":"2011","unstructured":"Chancellor MB, Smith CP (2011) Botulinum toxin in urology. Springer, Berlin. http:\/\/www.springer.com\/medicine\/urology\/book\/978-3-642-03579-1?changeHeader"},{"key":"308_CR9","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1097\/01.phm.0000219229.92056.c2","volume":"85","author":"MB Chancellor","year":"2006","unstructured":"Chancellor MB, Anderson RU, Boone TB (2006) Pharmacotherapy for neurogenic detrusor overactivity. Am J Phys Med Rehabil 85:536\u2013545","journal-title":"Am J Phys Med Rehabil"},{"key":"308_CR10","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/ncpuro1124","volume":"5","author":"MB Chancellor","year":"2008","unstructured":"Chancellor MB, Fowler CJ, Apostolidis A et al (2008) Drug insight: biological effects of botulinum toxin A in the lower urinary tract. Nat Clin Pract Urol 5:319\u2013328","journal-title":"Nat Clin Pract Urol"},{"key":"308_CR12","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.eururo.2008.06.047","volume":"54","author":"CR Chapple","year":"2008","unstructured":"Chapple CR, Khullar V, Gabriel Z et al (2008) The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 54:543\u2013562","journal-title":"Eur Urol"},{"key":"308_CR13","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.eururo.2013.04.001","volume":"64","author":"C Chapple","year":"2013","unstructured":"Chapple C, Sievert K-D, MacDiarmid S et al (2013) OnabotulinumtoxinA 100 u significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomized, double-blind, placebo-controlled trial. Eur Urol 64:249\u2013256","journal-title":"Eur Urol"},{"key":"308_CR14","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1097\/01.ju.0000137844.77524.97","volume":"172","author":"YC Chuang","year":"2004","unstructured":"Chuang YC, Yoshimura N, Huang CC, Chiang PH, Chancellor MB (2004) Intravesical botulinum toxin A administration produces analgesia against acetic acid induced bladder pain responses in rats. J Urol 172:1529\u20131532","journal-title":"J Urol"},{"issue":"5","key":"308_CR15","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1111\/j.1464-410X.2006.06479.x","volume":"98","author":"YC Chuang","year":"2006","unstructured":"Chuang YC, Chiang PH, Yoshimura N, De Miguel F, Chancellor MB (2006) Sustained beneficial effects of intraprostatic botulinum toxin type A on lower urinary tract symptoms and quality of life in men with benign prostatic hyperplasia. BJU Int 98(5):1033\u20131037","journal-title":"BJU Int"},{"key":"308_CR16","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.eururo.2011.07.002","volume":"60","author":"F Cruz","year":"2011","unstructured":"Cruz F, Herschorn S, Aliotta P et al (2011) Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomized, double-blind, placebo-controlled trial. Eur Urol 60:742\u2013750","journal-title":"Eur Urol"},{"key":"308_CR20","doi-asserted-by":"publisher","unstructured":"Denys P, Del Popolo G, Amarenco G, Dysport Study Group et al (2016) Efficacy and safety of two administration modes of an intra-detrusor injection of 750 units dysport\u00ae (abobotulinumtoxinA) in patients suffering from refractory neurogenic detrusor overactivity (NDO): a randomised placebo-controlled phase IIa study. Neurourol Urodyn. https:\/\/doi.org\/10.1002\/nau.22954","DOI":"10.1002\/nau.22954"},{"key":"308_CR22","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/S0022-5347(17)42717-0","volume":"139","author":"D Dykstra","year":"1988","unstructured":"Dykstra D, Sidi A, Scott A et al (1988) Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol 139:919\u2013922","journal-title":"J Urol"},{"key":"308_CR24","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1136\/jnnp.2004.045765","volume":"76","author":"P Gallien","year":"2005","unstructured":"Gallien P, Reymann J-M, Amarenco G et al (2005) Placebo controlled, randomized, double blind study of the effects of botulinum A toxin on detrusor sphincter dyssynergia in multiple sclerosis patients. J Neurol Neurosurg Psychiatry 76:1670\u20131676","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"308_CR25","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1097\/01.AOG.0000141441.41178.6b","volume":"104","author":"S Ghazizadeh","year":"2004","unstructured":"Ghazizadeh S, Nikzad M (2004) Botulinum toxin in the treatment of refractory vaginismus. Obstet Gynecol 104:922\u2013925","journal-title":"Obstet Gynecol"},{"key":"308_CR26","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1016\/j.juro.2012.01.125","volume":"187","author":"D Ginsberg","year":"2012","unstructured":"Ginsberg D, Gousse A, Keppenne V et al (2012) Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. J Urol 187:2131\u20132139","journal-title":"J Urol"},{"key":"308_CR27","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s12325-013-0054-z","volume":"30","author":"D Ginsberg","year":"2013","unstructured":"Ginsberg D, Cruz F, Herschorn S et al (2013) OnabotulinumtoxinA is effective in patients with urinary incontinence due to neurogenic detrusor activity regardless of concomitant anticholinergic use or neurologic etiology. Adv Ther 30:819\u2013833","journal-title":"Adv Ther"},{"key":"308_CR28","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1016\/j.juro.2015.01.087","volume":"193","author":"EA Gormley","year":"2015","unstructured":"Gormley EA, Lightner DJ, Faraday M et al (2015) Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA\/SUFU guideline amendment. J Urol 193:1572\u20131580","journal-title":"J Urol"},{"key":"308_CR29","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/j.juro.2015.01.086","volume":"193","author":"PM Hanno","year":"2015","unstructured":"Hanno PM, Erickson D, Moldwin R et al (2015) Diagnosis and treatment of interstitial cystitis\/bladder pain syndrome: AUA guideline amendment. J Urol 193:1545\u20131553","journal-title":"J Urol"},{"key":"308_CR31","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.urology.2006.08.1117","volume":"69","author":"HC Kuo","year":"2007","unstructured":"Kuo HC (2007) Recovery of detrusor function after urethral botulinum A toxin injection in patients with idiopathic low detrusor contractility and voiding dysfunction. Urology 69:57\u201361; discussion 61\u201352","journal-title":"Urology"},{"key":"308_CR32","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1111\/j.1464-410X.2009.08495.x","volume":"104","author":"HC Kuo","year":"2009","unstructured":"Kuo HC, Chancellor MB (2009) Comparison of intravesical botulinum toxin type A injections plus hydrodistention with hydrodistention alone for the treatment of refractory interstitial cystitis\/painful bladder syndrome. BJU Int 104:657\u2013661","journal-title":"BJU Int"},{"key":"308_CR35","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/S0090-4295(03)00477-1","volume":"62","author":"G Maria","year":"2003","unstructured":"Maria G, Brisinda G, Civello IM et al (2003) Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia; results of a randomized, placebo-controlled study. Urology 62:259\u2013264","journal-title":"Urology"},{"key":"308_CR36","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.juro.2014.02.004","volume":"192","author":"KT McVary","year":"2014","unstructured":"McVary KT, Roehrborn CG, Chartier-Kastler E et al (2014) A multicenter, randomized, double-blind, placebo controlled study of onabotulinumtoxinA 200 U to treat lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol 192:150\u2013156","journal-title":"J Urol"},{"key":"308_CR38","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1016\/j.juro.2012.12.022","volume":"189","author":"VW Nitti","year":"2013","unstructured":"Nitti VW, Dmochowski R, Herschorn S et al (2013) OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol 189:2186\u20132193","journal-title":"J Urol"},{"key":"308_CR43","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1056\/NEJM200003023420918","volume":"342","author":"B Schurch","year":"2000","unstructured":"Schurch B, Schmid D, Stohrer M et al (2000) Treatment of neurogenic incontinence with botulinum toxin. N Engl J Med 342:665","journal-title":"N Engl J Med"},{"key":"308_CR46","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S0361-9230(03)00114-X","volume":"61","author":"CP Smith","year":"2003","unstructured":"Smith CP, Boone TB, de Groat WC, Chancellor MB, Somogyi GT (2003) Effect of stimulation intensity and botulinum toxin isoform on rat bladder strip contractions. Brain Res Bull 61:165\u2013171","journal-title":"Brain Res Bull"},{"issue":"5","key":"308_CR47","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.urology.2004.06.073","volume":"64","author":"CP Smith","year":"2004","unstructured":"Smith CP, Radziszewski P, Borkowski A et al (2004) Botulinum toxin A has antinociceptive effects in treating interstitial cystitis. Urology 64(5):871\u2013875","journal-title":"Urology"},{"key":"308_CR49","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/j.neuint.2007.11.006","volume":"52","author":"CP Smith","year":"2008","unstructured":"Smith CP, Gangitano DA, Munoz A et al (2008) Botulinum toxin type A normalizes alterations in urothelial ATP and NO release induced by chronic spinal cord injury. Neurochem Int 52:1068\u20131075","journal-title":"Neurochem Int"},{"key":"308_CR50","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s00345-002-0301-4","volume":"20","author":"WF Stewart","year":"2003","unstructured":"Stewart WF, Van Rooyen JB, Cundiff GW et al (2003) Prevalence and burden of overactive bladder in the United States. World J Urol 20:327\u2013336","journal-title":"World J Urol"}],"container-title":["Handbook of Experimental Pharmacology","Botulinum Toxin Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/164_2019_308","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,5]],"date-time":"2021-01-05T19:43:39Z","timestamp":1609875819000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/164_2019_308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"ISBN":["9783030663056","9783030663063"],"references-count":33,"URL":"https:\/\/doi.org\/10.1007\/164_2019_308","relation":{},"ISSN":["0171-2004","1865-0325"],"issn-type":[{"value":"0171-2004","type":"print"},{"value":"1865-0325","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019]]},"assertion":[{"value":"20 June 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}